Artelo Biosciences, Inc.

ARTL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 94.7% and free cash flow fell 879.2%, each against the same quarter a year earlier.

2.70 0.04 −1.46%
Market cap
$1.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Aug '17 Aug '18 Aug '19 Aug '20 Aug '21 Aug '22 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
19.53 0.75 4.35 4.66 19.61 18.36 18.36 8.51 1.44 0.17
Net Debt/EBITDA
2.47 0.14 1.38 0.46 1.35 1.70 1.56 1.05 0.23 0.05
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
0.92 0.69 1.29 0.93 0.83 0.79 0.79 0.88 0.85 0.66
Capex/Depreciation
0.00 (2.67) (3,001.40) 0.00 — — — — — (0.30)
Interest Coverage
(110.86) — — (4,686.00) (3,720.50) (10,287.00) (2,057.40) — — (41.17)
ROE
(88.47%) (1,143.73%) (81.57%) (99.72%) (93.45%) (64.13%) (51.97%) (59.63%) (134.52%) (1,625.11%)
ROA
(81.80%) (482.55%) (63.15%) (85.74%) (87.44%) (61.00%) (49.37%) (55.51%) (110.77%) (343.49%)
ROIC
0.00% 0.00% (193.40%) (169.00%) (235.24%) 0.00% (191.07%) (468.04%) (1,217.24%) 0.00%
Return on Tangible Assets
(43.11%) 1,735.93% (63.48%) (253.54%) (75.96%) (58.20%) (58.20%) (95.87%) (1,251.72%) 384.56%
Average Days of Receivables
— 0.00 0.00 — — — — — — —
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.31 0.47 0.16 0.10 0.10 0.16 0.43 0.73
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% — 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(60.22) (3,221.60) (4,770.44) (2,898.00) (797.53) (2.81) (457.60) (448.47) (419.60) (225.25)
Cash per Share
159.11 674.80 4,915.56 1,428.00 1,307.14 6.19 916.46 569.73 117.49 15.75
Shareholders Equity per Share
151.33 (270.00) 6,068.00 2,583.33 1,563.90 6.85 1,108.74 642.19 143.57 (33.39)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
151.33 (270.00) 6,068.00 2,583.33 1,563.90 6.85 1,108.74 642.19 143.57 (33.39)
Free Cash Flow
(0.22) (1.61) (4.29) (4.35) (6.14) (7.96) (8.01) (8.21) (8.35) (8.58)
Working Capital
0.54 (0.14) 3.42 1.84 9.79 17.32 17.32 9.69 0.79 (3.35)
Capital Expenditures
— 0.00 (1.50) — — — — — — (0.06)
Net Current Asset Value
0.54 (0.14) 3.42 1.84 9.72 17.30 17.30 9.69 0.72 (3.38)
Other line items
Quick Ratio
19.48 0.68 4.33 4.28 19.14 17.57 16.07 8.08 1.32 0.15
Depreciation/Fixed assets
0.00 0.50 0.71 0.00 0.00 0.00 — — — 0.00
Cash ROIC
(19.40%) (795.85%) (43.43%) (72.25%) (27.78%) (21.56%) (22.60%) (37.01%) (160.73%) 1,277.08%
Accounts Receivable Turnover
— 0.00 0.00 — — — — — — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 — — — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 — — — — — —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(60.22) (3,220.00) (3,103.00) (2,898.00) (797.53) (2.81) (457.60) (448.47) (419.60) (223.62)
Capex per Share
0.00 (1.60) (1,667.44) 0.00 0.00 0.00 0.00 0.00 0.00 (1.63)
Average Receivables
— 0.02 0.02 — — — — — — —
Average Payables
0.02 0.28 0.44 0.42 0.48 — 0.69 1.07 1.46 2.36
Average Assets
0.29 0.49 3.44 5.43 8.51 16.53 20.42 16.73 8.87 3.75
Average Common Equity
0.27 0.20 2.66 4.67 7.96 15.72 19.40 15.58 7.30 0.79
Capex to Sales
— 0.00 0.00 — — — — — — 0.00

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026